解锁未来:精确的寡核酸疗法用于针对性治疗神经退行性疾病
Naitik Jain1, Amrita Arup Roy1, Geethu Madhusoodanan1
1Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.
International journal of biological macromolecules
|April 27, 2025
概括
开发新的寡核酸输送方法对于治疗超越阿尔茨海默氏症和帕金森症的神经退行性疾病至关重要. 克服血脑屏障是改善患者生活质量的关键.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药物运输 药物运输 药物运输
背景情况:
- 神经退行性疾病显著影响生活质量,需要先进的治疗策略.
- 寡核酸对精准医学有前途,但在穿越血脑屏障方面面临挑战.
- 本综述专门针对神经退行性疾病,不包括阿尔茨海默病和帕金森病.
研究的目的:
- 对神经退行性疾病的血脑屏障跨越寡核酸输送的当前挑战和进展进行审查.
- 探索各种中枢神经系统向策略,以提高治疗疗效.
- 讨论未来神经退行性疗法的监管和临床翻译方面.
主要方法:
- 关于向中枢神经系统的寡核酸输送系统的最新科学文献的综述.
- 分析化学结合,抗体-寡核酸结合物,聚焦超声波和病毒/纳米载体系统.
- 讨论每个交付方法的优势,局限性和潜在解决方案.
主要成果:
- 通过血脑屏障识别了寡核酸转移的重大障碍.
- 突出了包括化学修饰,抗体合物,聚焦超声波和纳米载体在内的各种传递策略.
- 评估了每个CNS传输方法的潜力和局限性.
结论:
- 创新的输送系统对于克服神经退行性疾病治疗的血脑屏障至关重要.
- 对优化寡核酸输送的进一步研究有望改善患者的治疗结果.
- 了解调节途径对于这些新疗法的临床转化至关重要.
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308


